No­var­tis plots to re­tain hives pa­tients with mon­o­clon­al an­ti­body that out­shines Xo­lair

Af­ter the loss of patent pro­tec­tion on its Roche-part­nered hives ther­a­py Xo­lair, No­var­tis $NVS has found its ex­per­i­men­tal mon­o­clon­al an­ti­body lige­lizum­ab sur­passed Xo­lair in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER